On December 16, 2020 Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, reported the completion of a $25 million Series A financing (Press release, Exo Therapeutics, DEC 16, 2020, View Source [SID1234572970]). Investors in the round included Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exo is building a deep pipeline of drug candidates that bind exosites, distal and unique binding pockets that reprogram enzyme activity for precise and robust therapeutic effect. Based on research from the labs of Professors David Liu and Alan Saghatelian, the company’s proprietary ExoSightTM platform is built upon advances in multiple technologies that enable discovery and optimization of exosite drugs, including structural and computational biology, protein engineering, and DNA-encoded libraries. Focusing on exosites overcomes the common challenges of competitive binding and off-target activity that occur with active site and allosteric modulators, potentially yielding better therapeutic windows, greater selectivity and fewer side effects.

"Exo is at the forefront of integrated exosite science, aiming to unlock previously intractable drug targets," said Michael Bruce, PhD, CEO of Exo Therapeutics. "We look to leverage our team’s unmatched expertise and focus on drugging exosites as we advance towards proof-of-concept drugs that we will progress to the clinic. With the support of world-class investors and rigorous foundational science, we are well-equipped to advance our pipeline of oncology and inflammation drug candidates in 2021."

"Exosites are compelling therapeutic targets as they avoid common challenges of targeting enzymes and are ubiquitous across the proteome allowing for a broad therapeutic potential," said Alan Saghatelian, PhD, Dr. Frederik Paulsen Chair, Salk Institute for Biological Studies.

"Exosites have demonstrated the ability to modulate cellular targets with precision and potency. The challenges of selectivity and traditional active site targeting are areas I have been focused on since my graduate work on receptors," said Thomas Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners. "The foundational work by professors Liu and Saghatelian provides elegant solutions for Exo to overcome these challenges. In addition, an experienced SAB with a track record of developing powerful therapeutics uniquely positions the company to develop a new class of small molecule drugs."

Proceeds from the financing will be used to advance therapeutic candidates derived from the company’s ExoSightTM platform towards proof-of-concept and into the clinic. Exo is advancing an initial portfolio of programs that are focused in oncology and inflammation by modulating enzyme activity in pathways where exosites are prevalent. The team expects to discover exosites in many important disease-causing pathways and will engage in strategic partnerships with biopharmaceutical companies.

In addition to Professors Liu and Saghatelian, Exo has assembled a Scientific Advisory Board that includes Professor Stuart Schreiber of the Broad Institute of MIT and Harvard, Professor Ben Cravatt, PhD of the Scripps Research Institute, and Professor Ben Ebert, MD, PhD of the Dana Farber Cancer Institute. Exo’s experienced, collaborative and dedicated team is passionate about pioneering exosite science to unlock breakthrough therapeutics.

On December 16, 2020, Cannabics Pharmaceuticals Inc. (the "Company") reported that it entered into a Securities Purchase Agreement (the "SPA") with an institutional investor (the "investor" or a "holder") to sell a new series of senior secured convertible notes (the "Convertible Notes") of the Company in a four tranche private placement (the "Private Placement") to the investor, with an aggregate principal amount of $2,750,000 having an aggregate original issue discount of 10%, and ranking senior to all outstanding and future indebtedness of the Company (Filing, 8-K, Cannabics Pharmaceuticals, DEC 16, 2020, View Source [SID1234573192]). Pursuant to the SPA, one Convertible Note (the "Initial Note") in an aggregate original principal amount of $825,000 will be issued to the investor in the first tranche in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"), and Rule 506(b) of Regulation D ("Regulation D") as promulgated by the United States Securities and Exchange Commission (the "SEC") under the 1933 Act, together with the issuance of warrants (the "Warrants" and, together with the Convertible Note, the "Securities") to acquire our common stock , as described below. The Initial Note has a face amount of $825,000 for which the Company shall receive cash proceeds of $750,000. Subject to the satisfaction of customary closing and equity conditions, at any time prior to December 31, 2021 (or such later date as the parties shall mutually agree), the Company has the right to require additional closings of tranches of additional notes (the "Additional Notes", and together with the Initial Notes, the "Notes") as follows: (x) $825,000 in aggregate principal of Additional Notes upon the effectiveness of a registration statement with respect to the shares of our common stock issuable upon conversion of the Notes (or, if earlier the date such underlying shares of our common stock are initially available to be resold pursuant to Rule 144 of the Securities Act of 1933, as amended (or if later, such date as the Company is then current in its public filings)) (the "Applicable Date"), (y) $550,000 in aggregate principal of Additional Notes upon the 90th calendar day anniversary of the Applicable Date and (z) $550,000 in aggregate principal of Additional Notes upon the 180th calendar day anniversary of the Applicable Date s. The Convertible Notes are being sold with an original issue discount of 10% and do not bear interest except upon the occurrence of an event of default.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following descriptions of the Convertible Notes, Warrants, Security and Pledge Agreement, Guaranty, Registration Rights Agreement and SPA are not complete and are qualified in their entirety by reference to the full text of such agreements, the forms of which are attached as Exhibit 10.1 through 10.6 to this Form 8-K, respectively.

On December 16, 2020 Transgene (Paris:TNG) (Euronext Paris: TNG) reported that Management will participate in the upcoming investor events set out below (Press release, Transgene, DEC 16, 2020, View Source [SID1234572949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Transgene will meet institutional investors at the 10th Annual LifeSci Advisors Corporate Access Event (virtual event) from January 6th to 14th, 2021 in conjunction with the J.P. Morgan Healthcare conference.

The Company will also attend:

Oddo BHF Digital Forum: January 7 to 13, 2021
Biomed Event (virtual event): January 26 & 27, 2021

On December 16, 2020 TRIUMF, Canada’s particle accelerator centre, reported it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines (Press release, Fusion Pharmaceuticals, DEC 16, 2020, View Source [SID1234573117]). Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed. The new collaboration will enable TRIUMF to significantly increase its production and delivery of actinium-225.

"Today’s announcement marks an important step in positioning Canada to play a leading role in the development and deployment of next-generation radiotherapies, and in ensuring that researchers and patients around the world have a stable supply of life-saving medical isotopes," said Dr. Jonathan Bagger, Director of TRIUMF. "Enabled by decades of public investment in TRIUMF’s infrastructure and research programs, this collaboration recognizes the laboratory’s capacity to drive innovation, moving this promising treatment closer to market."

"Given Fusion’s opportunity to expand our pipeline of actinium-based Targeted Alpha Therapies (TATs), and the importance of isotope production in the supply chain of radiopharmaceuticals, we will continue to proactively address and prioritize actinium supply in our strategic plans," said Dr. John Valliant, Chief Executive Officer of Fusion. "We are excited to collaborate with TRIUMF, a leader in isotope production, as part of these plans."

"With its Targeted Alpha Therapy platform technology, Fusion has an opportunity to impact the cancer treatment landscape," said Kathryn Hayashi, Chief Executive Officer of TRIUMF Innovations. "Through this collaboration agreement, we are partnering with a premier developer of innovative radiotherapies to deepen TRIUMF’s leadership position in isotope production to help save the lives of patients in Canada and around the world".

On December 16, 2020 Seagen Inc. (Nasdaq: SGEN) reported that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 2:00 p.m. Eastern Time (Press release, Seagen, DEC 16, 2020, View Source [SID1234572934]). The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!